Cowen and Company’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Cowen and Company’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,523	Closed	-$127K	–	752
2020 Q4	$127K	Buy	+5,523	New	+$70K	0.01%	204

Cowen and Company's PRVL Position: Q1 2021 in Review

Cowen and Company sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 5,523 shares — an estimated $127K sold.

Cowen and Company first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $127K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Cowen and Company reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Cowen and Company sold 5,523 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $127K.
Cowen and Company first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Cowen and Company's Prevail Therapeutics Inc. Common Stock position peaked at $127K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Cowen and Company's 13F filing for Q1 2021, filed 4 May 2021.